Plaque rupture, not plaque formation, is what actually kills — and that distinction has long frustrated cardiovascular researchers seeking targets beyond lipid lowering. A mechanistic study published in Redox Biology now identifies a previously uncharted pathway connecting perivascular adipose tissue (PVAT) dysfunction to iron-dependent cell death, opening a potentially actionable route to plaque stabilization without directly targeting the lipid core.
The investigation centered on CL-316243, a selective β3-adrenoceptor agonist, in atherosclerotic models. PVAT surrounding diseased arteries was found to exhibit significant ferroptotic activity — a regulated cell death mode driven by lipid peroxidation and iron dysregulation. CL-316243 treatment robustly suppressed ferroptotic markers in both isolated adipocytes and atherosclerotic PVAT in vivo. Downstream phenotypic consequences were substantial: treated plaques showed reduced necrotic core area, lower expression of the macrophage marker CD68 and matrix metalloproteinases, and increased collagen deposition — a composite profile consistent with a more stable, rupture-resistant lesion. The mechanistic axis traced to C/EBPβ, a transcription factor shown via CUT&Tag and dual-luciferase reporter assays to directly regulate GPX4 — the master ferroptosis suppressor — at a defined promoter binding motif. Knockdown of Cebpb abolished CL-316243's protective GPX4 upregulation, confirming pathway dependency.
This work is notable for establishing ferroptosis as a functional contributor to PVAT pathology rather than a bystander event, and for identifying a druggable receptor-transcription factor-antioxidant enzyme cascade. β3-adrenoceptor agonists are already clinically approved for overactive bladder (mirabegron), which lowers the translational barrier somewhat. Nevertheless, several caveats temper enthusiasm: the data appear to derive from preclinical models, and whether human PVAT ferroptosis tracks the same C/EBPβ-GPX4 axis remains unverified. The study also does not address systemic metabolic effects of β3 agonism, which could confound cardiovascular endpoints in human trials. As an incremental but mechanistically precise advance, this positions PVAT ferroptosis suppression as a credible, testable strategy for residual cardiovascular risk.